Streetbeat News

TEM

Tempus AI Inc.

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

43.90

Mkt cap

7.9B

Volume

11M

High

47.46

P/E Ratio

-7.57

52-wk high

91.45

Low

43.25

Div yield

N/A

52-wk low

22.89

Tempus (TEM) has announced the acquisition of Deep 6 AI to enhance its AI-driven clinical trial matching capabilities. This move aims to accelerate patient recruitment and revolutionize precision medicine.

Portfolio Pulse from

March 13, 2025 | 6:00 pm

Tempus AI, Inc. (NASDAQ: TEM) has acquired Deep 6 AI, enhancing its capabilities in AI-powered precision medicine and patient care. This acquisition aims to improve clinical trial processes and real-world evidence generation.

Portfolio Pulse from

March 11, 2025 | 9:30 pm

Tempus AI, trading under the symbol TEM, is leveraging artificial intelligence to improve healthcare outcomes. The stock recently saw a decline of 11.18%.

Portfolio Pulse from

February 28, 2025 | 11:30 am

Tempus AI's stock fell 15% following a weak Q4 performance, but the company maintains a strong EBITDA outlook. The acquisition of Ambry Genetics enhances its genomics capabilities, adding a West Coast lab and expanding inherited risk testing.

Portfolio Pulse from

February 26, 2025 | 5:00 pm

Tempus AI's Q4 results were slightly below expectations, but the company raised its 2025 revenue guidance, presenting a buying opportunity. With a focus on revenue growth and customer adoption, Tempus AI's 30% organic revenue growth and Ambry acquisition integration highlight its long-term potential.

Portfolio Pulse from

February 26, 2025 | 1:15 pm

Tempus AI, trading under NASDAQ: TEM, is an emerging player in the healthcare AI sector. The company shows promise for long-term growth and profitability by using AI to manage patient testing and assist physicians with diagnoses and treatment plans.

Portfolio Pulse from

February 26, 2025 | 12:30 pm

Tempus AI (NASDAQ:TEM) shares dropped over 13% following the release of their Q4 and full-year 2024 earnings results. The stock is known to be favored by Nancy Pelosi.

Portfolio Pulse from

February 25, 2025 | 5:00 pm

Tempus (TEM) reported its fourth-quarter earnings and revenues, which fell short of estimates. Despite strong segmental performance, the company is still facing operational losses.

Portfolio Pulse from

February 25, 2025 | 4:00 pm

Tempus AI's growth is slowing, raising doubts about its AI-led narrative. Despite revenue growth, it remains free cash flow negative with a weak balance sheet and significant net debt, potentially needing more capital by 2025.

Portfolio Pulse from

February 25, 2025 | 11:45 am

Tempus AI, Inc. (NASDAQ:TEM) held its Q4 2024 earnings call on February 24, 2025. Key participants included CEO Eric Lefkofsky and CFO Jim Rogers, with analysts from major financial institutions attending.

Portfolio Pulse from

February 25, 2025 | 3:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.